This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / Biond Biologics, GIBF $8M Investment
Business strategic investment

Biond Biologics, GIBF $8M Investment

Analysis based on 7 articles · First reported Jun 01, 2026 · Last updated Jun 01, 2026

Sentiment
70
Attention
4
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

This strategic investment and joint venture will likely boost the valuation of ADMA Biologics as it gains significant funding and market access in China. It also signals positive sentiment for the biotechnology sector, particularly for innovative oncology therapies, potentially attracting further investment in similar companies.

Biotechnology Pharmaceuticals Venture Capital
Event Summary

ADMA Biologics, a private clinical-stage biotechnology company, and Guangzhou-Israel Biotechnology Fund (GIBF), a life science investment fund, announced an $8 million strategic investment and the formation of a China-based joint venture. This partnership aims to accelerate the development of ADMA Biologics' innovative oncology pipeline, including lead programs BND-67 and BND-22, within the Chinese market. The collaboration leverages ADMA Biologics' scientific approaches and Guangzhou-Israel Biotechnology Fund's expertise in the Chinese biotechnology ecosystem, including clinical development and regulatory strategy. Ori Shilo and Avner Lushi both commented on the significance of this partnership for global pipeline advancement and value creation.

Entities Involved
stock
ADMA Biologics
ADMA Biologics received an $8 million strategic investment and formed a joint venture with Guangzhou-Israel Biotechnology Fund to advance its oncology pipeline in China, accelerating development of BND-67 and BND-22.
Importance 100.0 Sentiment 75.0
oth
Guangzhou-Israel Biotechnology Fund
Guangzhou-Israel Biotechnology Fund invested $8 million in ADMA Biologics and formed a joint venture to leverage its expertise in the Chinese biotechnology ecosystem, aiming to accelerate clinical development and expand Biond's pipeline in China.
Importance 90.0 Sentiment 70.0
cnt
China
China is the target market for the joint venture, providing a significant opportunity for the development and commercialization of ADMA Biologics' oncology programs.
Importance 60.0 Sentiment 50.0
per
Ori Shilo
Ori Shilo, CFO and Co-Founder of ADMA Biologics, commented on the strategic partnership, highlighting its importance for global pipeline advancement.
Importance 30.0 Sentiment 60.0
per
Avner Lushi
Avner Lushi, Managing Partner of Guangzhou-Israel Biotechnology Fund, expressed satisfaction with the partnership and its potential to create value in the Chinese biotech market.
Importance 30.0 Sentiment 60.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.